Appili was created to deliver innovative drug development programs for unmet patient needs across a broad spectrum of infectious diseases
Advancing DRUG DEVELOPMENT IN infectious disease AND BIODEFENSE to provide solutions to patients, doctors, and society
Potential first in-class vaccine candidate tackling a serious bioterrorism
threat
Liquid oral reformulation of metronidazole for the growing number of patients who are unable to take the current tablet treatment
EventFDA established a PDUFA action date for ATI-1501 of September 23, 2023 Government funding committed to enable Appili to […]
EventNOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia-June 29, […]
EventExecuted US$7.3M initial contract with U.S. Air Force Academy for ATI-1701 Upcoming PDUFA date of September 23, 2023 for […]
EventUpcoming PDUFA date of September 23, 2023 HALIFAX, Nova Scotia, May 24, 2023 – Appili Therapeutics Inc. (TSX:APLI; OTCQB: […]
EventFunding will enable Appili to advance it’s Biodefense Vaccine Candidate ATI-1701 to IND – NOT FOR DISTRIBUTION TO UNITED STATES […]
EventHALIFAX, Nova Scotia – April 18, 2023: Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical […]
EventAccomplished biopharmaceutical executive brings more than 25-years of experience leading vaccine and antibody product development for infectious disease indications Dr. […]
EventWashington, DC
View Event
EventToronto, ON
View Event
EventGrnoble Alpes, France
View Event
